Infant Bacterial Therapeutics

IBT Continues Development of Drug Candidate IBP-9414

IBT received results in August from the largest ever randomized clinical trial in premature infants. During the fall, IBT has continued to review the phase 3 results. Parts of the results have previously been communicated and presented by the study's principal investigator at the Hot Topics conference in Washington DC in early December. IBT has also met with the FDA during this quarter. After the continued review and dialog with the FDA, IBT sees no reasons to discontinue the drug development of IBP-9414 as previously decided. 



“It is satisfying that after the reviews in the fall, we will continue towards the launch of our drug IBP-9414 as soon as possible. This is good news for all infants who need our treatment to improve their chances of survival”, says Staffan Strömberg, CEO of IBT.

Datum 2024-12-20, kl 16:33
Källa MFN
Ungdomsdeal - 200 kr ! Just nu får alla nya kunder mellan 18 och 25 år 200 kr gratis när man skapar konto på Nordnet, insatt i fonden Nordnet One Balanserad. Bra läge att testa Nordnet!
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet